Clinical trials: Gastrointestinal Complications
Malignant Mesothelioma, Colorectal Cancer
Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
This is a first-in-human, single-arm, open-label, dose escalation clinical study to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics, immunogenicity and preliminary efficacy of UCMYM802…
- Conditions
- Malignant Mesothelioma, Colorectal Cancer, Bile Duct Cancer, Rectal Cancer
- Trial name
- NCT06256055
- Testing
- UCMYM802 Injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- UTC Therapeutics Inc.
Advanced Solid Cancer, Non Small Cell Lung Cancer
APG-2449 in Patients With Advanced Solid Tumors
APG-2449 is a novel, orally active, multi-targeted tyrosine kinase inhibitor, which inhibits FAK, ALK, and ROS1 with nanomolar potencies.
- Conditions
- Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer, Ovarian Cancer
- Trial name
- NCT03917043
- Testing
- APG-2449
- Where
- 9 sites in China
- Volunteers
- 165 people
- Sponsor
- Ascentage Pharma Group Inc.
Chronic Kidney Disease
Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients
The purpose of the study is to demonstrate the safety and immunogenicity of a new investigational hepatitis B virus vaccine, HEPLISAV-B, in patients 18 to 75 years of age who have progressive loss of kidney function.
- Trial name
- NCT00985426
- Testing
- HEPLISAV-B, Engerix-B
- Where
- United States
- Volunteers
- 521 people
- Sponsor
- Dynavax Technologies Corporation
Bladder Cancer, Gastric Cancer
Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
A phase 1/2, open-label, study to determine the safety and preliminary efficacy of APR-246 in combination with pembrolizumab in subjects with solid tumor malignancies.
- Conditions
- Bladder Cancer, Gastric Cancer, Non Small Cell Lung Cancer, NSCLC
- Trial name
- NCT04383938
- Testing
- APR-246 (eprenetapopt) + Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- Aprea Therapeutics
Peritoneal Carcinomatosis, Ovarian Cancer
Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis
RAD-18-001 is a First-In-Man, Dose Escalation study conducted at 2 sites. The dose escalation will be performed based on a 3 + 3 design. Increasing dose levels starting at 1 MBq will be followed by 2, 4 and 7 MBq.
- Trial name
- NCT03732768
- Testing
- Radspherin
- Where
- 4 sites in Belgium, Norway and 1 more
- Volunteers
- 21 people
- Sponsor
- Oncoinvent Solutions AS
Short Bowel Syndrome
Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)
The primary objective of the trial is to confirm the efficacy of glepaglutide in reducing parenteral support volume in patients with short bowel syndrome. Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.
- Trial name
- EASE SBS 1 (NCT03690206)
- Testing
- glepaglutide
- Where
- 29 sites in United States, Belgium and 7 more
- Volunteers
- 106 people
- Sponsor
- Zealand Pharma
Hepatorenal Syndrome
Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients
A study of ifetroban in the treatment of hepatorenal syndrome (HRS) in hospitalized adult patients to assess the safety and pharmacokinetics of 3 days of intravenous ifetroban.
- Trial name
- NCT01436500
- Testing
- Ifetroban Injection
- Where
- 12 sites in United States, India
- Volunteers
- 55 people
- Sponsor
- Cumberland Pharmaceuticals
Advanced Solid Tumors, Colorectal Cancer (CRC)
A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies
The goal of this study is to learn if KQB368 works to treat advanced solid malignancies in adults. The study will also learn about the safety of KQB368.
- Conditions
- Advanced Solid Tumors, Colorectal Cancer (CRC), Non-Small Cell Lung Cancer, Uterine Cancer
- Trial name
- NCT07542704
- Testing
- KQB368
- Where
- 14 sites in United States
- Volunteers
- 48 people
- Sponsor
- Kumquat Biosciences Inc.
Solid Tumors
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of escalating doses of RMC-5552 monotherapy in adult participants with relapsed/refractory solid tumors…
- Trial name
- NCT04774952
- Testing
- RMC-5552
- Where
- 8 sites in United States
- Volunteers
- 58 people
- Sponsor
- Revolution Medicines, Inc.
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Lung Cancer, Colon Cancer
A Study of PHN-010 in Patients With Advanced Solid Tumors
This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-010, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.
- Conditions
- Lung Cancer, Colon Cancer, Endometrial Cancer, Ovarian Cancer
- Trial name
- NCT06457997
- Testing
- PHN-010
- Where
- 8 sites in United States
- Volunteers
- 26 people
- Sponsor
- Pheon Therapeutics
Hemorrhage, Gastrointestinal, Myocardial Infarction
A Study of Channeling in the Use of Nonprescription Paracetamol and Ibuprofen in an Electronic Medical Records Database: Evidence and Implications
The Purpose of this study is to examine whether evidence of channeling exists by analyzing within a cohort of participants with first prescriptions of single-ingredient paracetamol or ibuprofen (or both) whether participants with…
- Conditions
- Hemorrhage, Gastrointestinal, Myocardial Infarction, Stroke, Kidney Diseases
- Trial name
- NCT02830178
- Where
- United States
- Volunteers
- 144,337 people
- Sponsor
- Janssen Research & Development, LLC
Cardiac Disorder, Hepatic Disorder
Kosmos Anatomical Object Labeling and View Identification Pivotal Study
This is a multi-site, multi-group study that obtained two sets of ultrasound scans from all enrolled participants. Participants underwent limited ultrasound scanning by both cardiac sonographers and abdominal sonographers.
- Conditions
- Cardiac Disorder, Hepatic Disorder, Spleen Disorder, Kidney Disorder
- Trial name
- NCT06468787
- Testing
- Kosmos Anatomical Object Labeling and View Identification Algorithms
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- EchoNous Inc.
Advanced Solid Tumors
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
- Trial name
- NCT05914116
- Testing
- DB-1311, Lopinavir and Ritonavir Tablets, itraconazole
- Where
- 107 sites in United States, Australia and 2 more
- Volunteers
- 862 people
- Sponsor
- DualityBio Inc.
Healthy
Effects of Teduglutide on Cardiac Repolarisation and Conduction in Healthy Male and Female Volunteers
The primary objective of this trial is to investigate if teduglutide has an effect on cardiac repolarisation (QT, QTc interval).
- Trial name
- NCT01028924
- Testing
- Teduglutide
- Where
- Germany
- Volunteers
- 72 people
- Sponsor
- Nycomed
Ovarian Neoplasms, Fallopian Tube Neoplasms
DNA Single Nucleotide Polymorphisms as Predictors of Toxicity
The presence of single nucleotide polymorphisms (SNPs) in genes involved in platinum and taxane metabolism and detoxification have been correlated to increased risk of severe adverse events (AEs) when patients receive these…
- Conditions
- Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms
- Trial name
- NCT02478476
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- OvaGene Oncology, Inc.
Renal Cell Carcinoma, Hepatocellular Carcinoma
Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients
The objective of this Post Marketing Surveillance (PMS) is to collect and describe safety and effectiveness profile of Cabometyx™ in real clinical practice setting, according to the approved labelling after the approval of…
- Conditions
- Renal Cell Carcinoma, Hepatocellular Carcinoma, Differentiated Thyroid Carcinoma
- Trial name
- NCT03776123
- Where
- 47 sites in South Korea
- Volunteers
- 347 people
- Sponsor
- Ipsen
Short Bowel Syndrome
VIBRANT Study of Vurolenatide in Adult Patients With Short Bowel Syndrome.
A Study of Vurolenatide in Adult Patients with Short Bowel Syndrome.
- Trial name
- NCT04988997
- Testing
- Vurolenatide 50mg/PBO, Vurolenatide 100mg/PBO, Vurolenatide 50/50 mg
- Where
- 6 sites in United States
- Volunteers
- 12 people
- Sponsor
- 9 Meters Biopharma, Inc.
Gastric Cancer, Triple Negative Breast Cancer
A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment
This is a a Multicenter, Open-label, Single-arm, Phase Ib Dose Escalation and Multi-cohort Expansion Clinical Study to Assess the Safety and Antitumor Activity of Niraparib in Combination with MGD013 in Patients with Advanced or…
- Conditions
- Gastric Cancer, Triple Negative Breast Cancer, Biliary Tract Carcinoma, Endometrial Carcinoma
- Trial name
- NCT04178460
- Testing
- Niraparib combined with MGD013
- Where
- 19 sites in China
- Volunteers
- 60 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Triple Negative Breast Cancer, Endometrial Cancer
A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors
This is an open-label, multi-center, non-randomized, Phase 1b/2 study to assess the safety and efficacy of fruquintinib in combination with tislelizumab in patients with locally advanced or metastatic solid tumors.
- Conditions
- Triple Negative Breast Cancer, Endometrial Cancer, Solid Tumor, Unspecified, Adult, Colorectal Cancer
- Trial name
- NCT04577963
- Testing
- Fruquintinib, Tislelizumab
- Where
- 16 sites in United States
- Volunteers
- 52 people
- Sponsor
- Hutchmed